Vnitr Lek 2021, 67(7):E18-E23 | DOI: 10.36290/vnl.2021.116

Amiodarone induced pulmonary toxicity

Martin Hudec^{1, 2}, Petra Vysočanová^{1, 2}, Vojtěch Brázdil^{1, 2}, Martin Poloczek^{1, 2}, Martin Hetmer^{1, 2}, Jiřina Little³, Martina Doubková^{2, 4}, Petr Kala^{1, 2}

¹ Interní kardiologická klinika Fakultní nemocnice Brno

² Lékařská fakulta Masarykovy univerzity Brno

³ Klinika radiologie a nukleární medicíny Fakultní nemocnice Brno

⁴ Klinika nemocí plicních a tuberkulózy Fakultní nemocnice Brno

Amiodarone is one of the more frequently used drugs in the treatment of supraventricular and ventricular arrhythmias. Many adverse effects, more or less serious, are associated with its administration. Amiodaron-induced pulmonary toxicity (AIPT) is quite rare but represents one of the most severe adverse effects with high mortality. We present an 80 years old patient, who used amidorane due to paroxysmal atrial fibrillation for several years. Within 3 months, he was repeatedly hospitalized for a bilateral pneumonia. Eventually, AIPT was diagnosed. Early diagnosis, proper therapy of AIPT and changed antiarrhythmic therapy has significantly improved the clinical status of our patient. In this case we demonstrate typical clinical presentations of AIPT as well as the most common diagnostic procedures and recommended treatment methods. Finally, some other commonly used therapeutical options for supraventricular arrhythmias are mentioned. Future options are outlined.

Keywords: amiodarone, AIPT, amiodarone induced pulmonary toxicity, amiodarone lung.

Published: November 1, 2021  Show citation